Picture of Takeda Pharmaceutical Co logo

TAK Takeda Pharmaceutical Co News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareConservativeLarge CapNeutral

REG - Marshall Wace LLP Takeda Pharma.Co.Ltd - Form 8.3 - Takeda Pharmaceutical Co Ltd





 




RNS Number : 4139M
Marshall Wace LLP
07 January 2019
 

FORM 8.3

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1.         KEY INFORMATION

 

(a) Full name of discloser:

Marshall Wace LLP (on behalf of itself and its affiliates)

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

     The naming of nominee or vehicle companies is insufficient.  For a trust, the trustee(s), settlor and beneficiaries must be named.


(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

     Use a separate form for each offeror/offeree

Takeda Pharmaceutical Company Limited

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:


(e) Date position held/dealing undertaken:

     For an opening position disclosure, state the latest practicable date prior to the disclosure

04 Jan 2019

(f)  In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

     If it is a cash offer or possible cash offer, state "N/A"

YES

If YES, specify which:

Shire plc

 

2.         POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a)        Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

Ordinary shares (ISIN: JP3463000004) - interest and short positions partially held via ADSs (ISIN: US8740602052)

 

 

Interests

Short positions


Number

%

Number

%

(1) Relevant securities owned and/or controlled:

1,756,662

0.22%

834,638

0.11%

(2) Cash-settled derivatives:

 



1,239,566

0.16%

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:





 

     TOTAL:

1,756,662

0.22%

2,074,204

0.26%

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b)        Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:


Details, including nature of the rights concerned and relevant percentages:


 

 

3.         DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a)        Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

Ordinary Shares

Sale

888

JPY 3652.4502

Ordinary Shares

Sale

60

JPY 3645.7333

Ordinary Shares

Sale

10,500

JPY 3672.5667

Ordinary Shares

Purchase

34,700

JPY 3675.9597

Ordinary Shares

Sale

20

JPY 3674

Ordinary Shares

Sale

128

JPY 3683.125

Ordinary Shares

Sale

290

JPY 3672.3914

Ordinary Shares

Sale

502

JPY 3686.1434

Ordinary Shares

Sale

1,544

JPY 3675.5941

Ordinary Shares

Sale

15,868

JPY 3626.4532

ADS

Sale

1,435

USD 17.262923

ADS

Sale

1,761

USD 17.262923

ADS

Sale

9,104

USD 17.262923

ADS

Sale

82

USD 17.257143

ADS

Sale

100

USD 17.257143

ADS

Sale

518

USD 17.257143

ADS

Sale

13

USD 17.4

ADS

Sale

11

USD 17.4

ADS

Sale

70

USD 17.4

ADS

Sale

378

USD 17.31948

ADS

Sale

462

USD 17.31948

ADS

Sale

2,361

USD 17.321041

ADS

Sale

352

USD 17.289753

ADS

Sale

164

USD 17.375714

ADS

Sale

1,484

USD 17.316301

ADS

Sale

13,283

USD 17.308048

ADS

Sale

1,795

USD 17.331998

ADS

Sale

2,707

USD 17.301574

ADS

Sale

1,625

USD 17.376622

ADS

Sale

1,236

USD 17.392021

ADS

Sale

8,339

USD 17.377115

ADS

Sale

927

USD 17.3939

ADS

Sale

1,217

USD 17.378607

ADS

Sale

5,911

USD 17.391484

ADS

Sale

16,329

USD 17.3759

ADS

Sale

2,475

USD 17.385

ADS

Sale

3,164

USD 17.3764

ADS

Purchase

2,886

USD 17.712003

ADS

Purchase

200

USD 17.665

ADS

Purchase

18,200

USD 17.706648

ADS

Purchase

24,000

USD 17.716292

ADS

Purchase

17,400

USD 17.713017

ADS

Purchase

19,906

USD 17.707005

ADS

Purchase

37,215

USD 17.7069

ADS

Sale

59,549

USD 17.79

 

(b)        Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

Ordinary Shares

CFD

Increasing a short position

72

JPY 3680

Ordinary Shares

CFD

Increasing a short position

2,512

JPY 3652.935591

Ordinary Shares

CFD

Increasing a short position

25,632

JPY 3627.904209

Ordinary Shares

CFD

Increasing a short position

140

JPY 3649.685714

Ordinary Shares

CFD

Increasing a short position

24,200

JPY 3677.431818

Ordinary Shares

CFD

Increasing a short position

610

JPY 3664.928689

Ordinary Shares

CFD

Increasing a short position

80

JPY 3674

Ordinary Shares

CFD

Increasing a short position

2,456

JPY 3669.801591

Ordinary Shares

CFD

Increasing a short position

298

JPY 3681.731544

ADS

CFD

Reducing a short position

59,549

USD 17.79

 

(c)        Stock-settled derivative transactions (including options)

 

(i)         Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit









 

(ii)        Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit





 

 

 

(d)        Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)


 

 



 

 

4.         OTHER INFORMATION

 

(a)        Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included.  If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

(b)        Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i)  the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

(c)        Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

 

 

Date of disclosure:

07 Jan 2019

Contact name:

Matthew Rooney

Telephone number:

020 7316 2253

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RETBSGDBUSGBGCR

Recent news on Takeda Pharmaceutical Co

See all news